| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000043073 |
| Receipt No. | R000049176 |
| Scientific Title | A clinical study to evaluate the safety of plant-extracts containing foods. -- Randomized, Placebo controlled, Double-Blind Parallel Study -- (SME-2020-01-HRCT) |
| Date of disclosure of the study information | 2021/02/04 |
| Last modified on | 2021/08/04 (Ver. 3) |
| Basic information | ||
| Public title | A clinical study to evaluate the safety of plant-extracts containing foods. (SME-2020-01-HRCT) | |
| Acronym | A clinical study to evaluate the safety of plant-extracts containing foods. | |
| Scientific Title | A clinical study to evaluate the safety of plant-extracts containing foods. -- Randomized, Placebo controlled, Double-Blind Parallel Study -- (SME-2020-01-HRCT) | |
| Scientific Title:Acronym | A clinical study to evaluate the safety of plant-extracts containing foods. | |
| Region |
|
|
| Condition | |||
| Condition | Not applicable | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the safety of plant-extracts foods. |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Incidence of adverse reactions |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Daily intake of test food for four weeks | |
| Interventions/Control_2 | Daily intake of control food for four weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Males and females who are -> 20 years old at the time of IC acquisition and <65 years old at the end of food intake
(2) Those who can get blood drawing, urine collection, and physical tests on the designated day (3) Those who have submitted written informed consent after fully understanding the purpose and content of this study. |
|||
| Key exclusion criteria | (1) Those who have difficulty in swallowing
(2) Those who are receiving any treatment at the screening (3) Those with systolic blood pressure less than 90 mmHg at the start of ingestion (4) Women who are/might be pregnant or lactating during the study (5) Those who have taken >=200 mL whole blood or blood donation within 4 weeks before the start of the intake (6) Men who have taken =>400 mL whole blood within 12 weeks before the start of intake (7) Women who have taken =>400 mL whole blood within 16 weeks before the start of intake (8) Men who have taken =>1,200 mL whole blood total (including the sampling of this study) within 12 months before the start of intake (9) Women who have taken =>800 mL whole blood total (including the sampling of this study) within 12 months before the start of intake (10) Those who are participating in other study or planning to participate or participated within the past 4 weeks. (11) Those who are: a) heart, liver, or kidney disease (including complications of other diseases) b) having a history of cardiovascular disease c) diabetes d) allergic to test foods e) undergoing treatment for or have a history of serious illnesses such as cancer and tuberculosis f) positive or suspected to be positive in the infectious disease test (12) Those who regularly use pharmaceuticals (including quasi-drugs), foods for specified health use, foods with functional claims or health foods. (13) Those who smoke an average of 21 or more cigarettes in a day (14) Those who drink an average of more than 60 g of pure alcohol in a day (15) Those who have an extremely irregular eating habit (16) Shift workers or late night workers (17) Others who are judged inappropriate for participant by the investigator |
|||
| Target sample size | 48 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | SUNTORY MONOZUKURI EXPERT LIMITED | ||||||
| Division name | HE Center | ||||||
| Zip code | 135-8631 | ||||||
| Address | 2-3-3 Daiba, Minato-ku, Tokyo, Japan | ||||||
| TEL | 03-5579-1277 | ||||||
| Hidenori_Obata@suntory.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | SUNTORY MONOZUKURI EXPERT LIMITED | ||||||
| Division name | HE Center | ||||||
| Zip code | 135-8631 | ||||||
| Address | 2-3-3 Daiba, Minato-ku, Tokyo, Japan | ||||||
| TEL | 03-5579-1277 | ||||||
| Homepage URL | |||||||
| N_Sekiguchi@suntory.co.jp | |||||||
| Sponsor | |
| Institute | SUNTORY MONOZUKURI EXPERT LIMITED |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Suntory Wellness Limited |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Fukuhara Clinic Clinical Trial Review Committee |
| Address | 3-1-15 Shimamatsuhigashimachi, Eniwa-shi, Hokkaido |
| Tel | 0123-36-8029 |
| d-kameda@mediffom.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049176 |